IMANEO acquired by PARQUEST CAPITAL
Context
Parquest acquired a majority stake in the newly formed Imaneo group from its 70 associate radiologists. The transaction was the result of a competitive process involving both French and international private equity funds, as well as corporate interest from the life sciences sector. This strategic operation facilitates the merger of three independent radiology practices into a single unified platform. The associate radiologists, who were already shareholders in their respective legacy firms, reinvested significantly to retain nearly 50% of the new group's capital. The investment strategy is focused on structuring the newly created entity's management and operations to allow medical staff to focus on clinical practice while providing the financial resources for aggressive organic and external growth. A unitranche debt facility, including dedicated capital expenditure lines, was secured to fund innovation in medical technology and the acquisition of additional radiology practices across the region.
IMANEO, which reported an EBITDA margin of in 2022, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Established in 2023 through the strategic merger of three prominent medical imaging entities based in Montpellier (CRP, Imacam, and I-Seris), Imaneo is a major regional player in the Occitanie healthcare market. The group provides comprehensive diagnostic imaging services through a collaborative network of specialized clinics. With a team of 70 associate radiologists and approximately 350 employees, the organization focuses on delivering high-quality medical care while leveraging shared resources to invest in technological advancements. The group is structured as a unified platform designed to integrate modern tools, including artificial intelligence solutions for diagnostics, and to attract new medical talent. By consolidating local expertise, the entity serves as a medical-led platform capable of addressing the growing demand for specialized outpatient care in southern France.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Health Providers
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 08/2023 | BAIN CAPITAL | ESTIA HEALTH | AUSTRALIA | Nursing Homes |
| 07/2023 | MEDIAN KLINIKEN | HESTIA ALLIANCE | SPAIN | Clinics / Hospitals |
| 06/2023 | Levine Leichtman Capital Partners | SEV Laser | UNITED STATES | Aesthetic & Cosmetic Clinics |
| 06/2023 | ARDIAN | MON VETO | FRANCE | Vet Clinics |
| 11/2022 | RADNET | HEART & LUNG IMAGING | UNITED KINGDOM | Radiology |
| 10/2022 | CBPE CAPITAL | VEINCENTRE | UNITED KINGDOM | Aesthetic & Cosmetic Clinics |
| 09/2022 | EURAZEO | IMAPOLE | FRANCE | Radiology |
| 09/2022 | ORADIANSE | REVEL | FRANCE | Radiology |
| 08/2022 | FREEMAN SPOGLI | EVERVET PARTNERS | UNITED STATES | Vet Clinics |
| 07/2022 | ANDERA PARTNERS | GROUPE RESONANCE IMAGERIE | FRANCE | Radiology |
REFERENCES
Valuation range: EV 100M - 350M EUR
Revenue range: 50M - 100M EUR
EBITDA range: 5M - 25M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of IMANEO by PARQUEST CAPITAL are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: imaneo
Acquirer: parquest capital